Modulation of immunity and the inflammatory response: A new target for treating drug-resistant epilepsy

Current Neuropharmacology

Volumn 11, Issue 1, 2013, Pages 114-127

  Yu, Nian ^a   Liu, Hao ^b   Di, Qing ^a  

^a THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Auto antibodies; Cytokines; Drug Resistant Epilepsy; Immunity; Inflammation

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL] BENZENESULFONAMIDE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTICONVULSIVE AGENT; AUTOANTIBODY; CORTICOTROPIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DEFLAZACORT; DEXAMETHASONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GANAXOLONE; GLUTAMIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MULTIDRUG RESISTANCE PROTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL) METHANESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PADGEM PROTEIN; PREDNISONE; PROSTAGLANDIN E2; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTICONVULSANT ACTIVITY; ASTROCYTOSIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; ELECTROCONVULSIVE THERAPY; EPILEPSY; GLIOSIS; HASHIMOTO ENCEPHALOPATHY; HUMAN; IMMUNITY; IMMUNOTHERAPY; INFLAMMATION; KETOGENIC DIET; LYMPHATIC DRAINAGE; MESIAL TEMPORAL LOBE EPILEPSY; MULTIPLE SCLEROSIS; NONHUMAN; PANENCEPHALITIS; PARANEOPLASTIC NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PROTEIN EXPRESSION; REVIEW; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION;

EID: 84874988574     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015913804999540     Document Type: Review

References (165)

1. International League Against Epilepsy. ELAE commission report. The epidemiology of the epilepsies. future directions. Epilepsia, 1997, 38(5), 614-688.
2. Fisher, R.S., van Emde Boas, W., Blume, W., Elger, C., Genton, P., Lee, P., Engel, J. Jr. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia, 2005, 46(4), 470-472.
3. Shorvon, S.D. Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958. Epilepsia, 2009, 50(Suppl 3): 69-92.
4. Shorvon, S.D. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia, 2009, 50 (Suppl 3): 93-130.
5. Kwan, P., Sander, J.W. The natural history of epilepsy: an epidemiological view. J. Neurol. Neurosurg. Psychiatry., 2004, 75(10), 1376-1381.
6. Kwan, P., Brodie, M.J. Early identification of refractory epilepsy. N. Engl. J. Med., 2000, 342(5), 314-319.
7. Kwan, P., Schachter, S.C., Brodie, M.J. Drug-resistant epilepsy. N. Engl. J. Med., 2011, 365(10), 919-926.
8. Kossoff, E.H. Intractable childhood epilepsy: choosing between the treatments. Semin. Pediatr. Neurol., 2011, 18(3), 145-149.
9. Peterman, M.G. Therapy of epilepsy in children. Am. J. Psychiat., 1936, 92, 1433-1438.
10. Arana, A., Wentworth, C.E., Ayuso-Mateos, J.L., Arellano, F.M. Suicide-Related Events in Patients Treated with Antiepileptic Drugs. N. Engl. J. Med., 2010, 363(6), 542-551.
11. Greenwood, R.S. Adverse Effects of Antiepileptic Drugs. Epilepsia, 2000, 41(Suppl s2) S42-S52.
12. Sillanpää M., Shinnar S. Long-term mortality in childhood-onset epilepsy. N. Engl. J. Med., 2010, 363(26), 2522-2529.
13. Chen, J.W., Wasterlain, C.G. Status epilepticus: pathophysiology and management in adults. Lancet Neurol., 2006, 5(3), 246-256.
14. Vezzani, A. Innate immunity and inflammation in temporal lobe epilepsy: new emphasis on the role of complement activation. Epilepsy Curr., 2008, 8(3), 75-77.
15. Vezzani, A., Granata, T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia, 2005, 46(11), 1724-1743.
16. Vezzani, A., French, J., Bartfai, T., Baram, T.Z. The role of inflammation in epilepsy. Nat. Rev. Neurol., 2011, 7(1), 31-40.
17. Mraovitch, S. Isocortical hyperemia and allocortical inflammation and atrophy following generalized convulsive seizures of thalamic origin in the rat. Cell Mol. Neurobiol., 2003, 23(4-5), 773-791.
18. Choi, J., Koh, S. Role of brain inflammation in epileptogenesis. Yonsei. Med. J., 2008, 49(1), 1-18.
19. Quek, A.M., Britton, J.W., McKeon, A., So, E., Lennon, V.A., Shin, C., Klein C.J., Watson R.E. Jr., Kotsenas A.L., Lagerlund, T.D., Cascino, G.D., Worrell, G.A., Wirrell, E.C., Nickels, K.C., Aksamit, A.J., Noe, K.H., Pittock, S.J. Autoimmune Epilepsy: Clinical Characteristics and Response to Immunotherapy. Arch. Neurol. 2012, 69(5), 582-593.
20. Kwan, P., Arzimanoglou, A., Berg, A.T., Brodie M.J., Allen H. W., Mathern, G., Moshé, S.L., Perucca E., Wiebe, S., French, J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6), 1069-1077.
21. Kwan, P., Brodie, M.J. Definition of refractory epilepsy: defining the indefinable? Lancet Neurol., 2010, 9(1), 27-29.
22. Hughes, J.R. One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurol. Res., 2008, 30 (9), 920-925.
23. Pachter, J.S., de Vries, H.E., Fabry, Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J. Neuropathol. Exp. Neurol., 2003, 62(6), 593-604.
24. Engelhardt, B. The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr. Pharm. Des., 2008, 14(16), 1555-1565.
25. Damani, M.R., Zhao, L., Fontainhas, A.M., Amaral, J., Fariss, R.N., Wong, W.T. Age-related alterations in the dynamic behavior of microglia. Aging Cell, 2011, 10(2), 263-276.
26. Vezzani, A., Friedman, A. Brain inflammation as a biomarker in epilepsy. Biomark. Med., 2011, 5(5), 607-614.
27. Aronica, E., Crino, P.B. Inflammation in epilepsy: clinical observations. Epilepsia, 2011, 52(Suppl 3), 26-32.
28. Nabbout, R., Vezzani, A., Dulac, O., Chiron, C. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol., 2011, 10(1), 99-108.
29. Specchio, N., Claps, D., Vigevano, F., Fusco, L. Refractory focal epilepsy following acute encephalopathy with inflammationmediated status epilepticus. Seizure, 2011, 20(10), 824-825.
30. Riazi, K., Galic, M.A., Pittman, Q.J. Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res., 2010, 89(1), 34-42.
31. Nielsen, K.A., Hansen, E.L., Gille, S. Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes. Scand. J. Clin. Lab. Invest., 2007, 67(3), 280-290.
32. Yu, N., Di, Q., Liu, H., Hu, Y., Jiang, Y., Yan, Y.K., Zhang, Y.F., Zhang Y.D. Nuclear factor-kappa B activity regulates brain expression of P-glycoprotein in the kainic acid-induced seizure rats. Mediators Inflamm., 2011, 2011, 670613.
33. Li, G., Bauer, S., Nowak, M., Norwood, B., Tackenberg, B., Rosenow, F., Knake, S., Oertel, W.H., Hamer, H.M. Cytokines and epilepsy. Seizure, 2011, 20(3), 249-256.
34. Belardelli, F. Role of interferons and other cytokines in the regulation of the immune response. APMIS, 1995, 103(3), 161-179.
35. Vezzani, A., Balosso, S., Ravizza, T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav. Immun., 2008, 22(6), 797-803.
36. Fabene P.F., Bramanti P., Constantin G. The emerging role for chemokines in epilepsy. J. Neuroimmunol., 2010, 224(1-2), 22-27.
37. Vezzani, A., Maroso, M., Balosso, S., Sanchez M.A., Bartfai, T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav. Immun., 2011, 25(7), 1281-1289.
38. Maroso, M., Balosso, S., Ravizza T., Liu, J., Bianchi, M.E., Vezzani, A. Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and highmobility group box 1. J. Intern. Med., 2011, 270(4), 319-326.
39. Maroso, M., Balosso, S., Ravizza, T., Liu, J., Aronica, E., Iyer, A. M, Rossetti, C., Molteni, M., Casalgrandi, M., Manfredi A.A., Bianchi, M.E., Vezzani, A. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med., 2010, 16(4), 413-419.
40. Rao R.S., Prakash A., Medhi B. Role of different cytokines and seizure susceptibility: a new dimension towards epilepsy research. Indian J. Exp. Biol., 2009, 47(8), 625-634.
41. Bernardino, L., Ferreira, R., Cristóvao, A.J., Sales, F., Malva, J.O. Inflammation and neurogenesis in temporal lobe epilepsy. Curr. Drug Targets CNS Neurol. Disord., 2005, 4(4), 349-360.
42. Johnson, E.A., Kan, R.K. The acute phase response and somaninduced status epilepticus: temporal, regional and cellular changes in rat brain cytokine concentrations. J. Neuroinflammation, 2010, 7, 40.
43. Takemiya, T., Maehara, M., Matsumura, K., Yasuda, S., Sugiura, H., Yamagata, K. Prostaglandin E2 produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region. Neurosci. Res., 2006, 56(1), 103-110.
44. Schlichtiger, J., Pekcec, A., Bartmann, H., Winter, P., Fuest, C., Soerensen, J., Potschka, H. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br. J. Pharmacol., 2010, 160(5), 1062-1071.
45. Claycomb, R.J., Hewett, S.J., Hewett, J.A. Neuromodulatory role of endogenous interleukin-1β in acute seizures: possible contribution of cyclooxygenase-2. Neurobiol. Dis., 2012, 45(1), 234-242.
46. Hulkkonen, J., Koskikallio, E., Rainesalo, S., Keränen, T., Hurme, M., Peltola J. The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients. Epilepsy Res., 2004, 59(2-3), 199-205.
47. Yu, N., Di, Q., Hu, Y., Zhang, Y.F., Su, L.Y., Liu, X.H., Li, L.C. A meta-analysis of pro-inflammatory cytokines in the plasma of epileptic patients with recent seizure. Neurosci. Lett., 2012, 514(1), 110-115.
48. Hirvonen, J., Kreisl, W.C., Fujita, M., Dustin, I., Khan, O., Appel, S., Zhang, Y., Morse, C., Pike V.W., Innis, R.B., Theodore, W.H. Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. J. Nucl. Med., 2012, 53(2), 234-240.
49. Zou, J., Wang, Y.X., Dou, F.F., Lü, H.Z., Ma, Z.W., Lu, P.H., Xu, X.M. Glutamine synthetase downregulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem. Int., 2010, 56(4), 577-584.
50. Saito, O., Svensson, C.I., Buczynski, M.W., Wegner, K., Hua, X.Y., Codeluppi S., Schaloske, R.H., Deems, R.A., Dennis, E.A., Yaksh, T.L. Spinal glial TLR4-mediated nociception and production of prostaglandin E(2) and TNF. Br. J. Pharmacol., 2010, 160(7), 1754-1764.
51. Grazia, de Simoni, M., Imeri, L., De Matteo, W., Perego, C., Simard, S., Terrazzino, S. Sleep regulation: interactions among cytokines and classical neurotransmitters. Adv. Neuroimmunol., 1995, 5(2), 189-200.
52. Baamonde, A., Hidalgo, A., Menéndez, L. Involvement of glutamate NMDA and AMPA receptors, glial cells and IL-1β in the spinal hyperalgesia evoked by the chemokine CCL2 in mice. Neurosci. Lett., 2011, 502(3), 178-181.
53. Marcon, J., Gagliardi, B., Balosso, S., Maroso, M., Noé, F., Morin, M., Lerner-Natoli, M., Vezzani, A., Ravizza, T. Age-dependent vascular changes induced by status epilepticus in rat forebrain: implications for epileptogenesis. Neurobiol. Dis., 2009, 34(1), 121-132.
54. Rigau V., Morin, M., Rousset, M.C., de Bock, F., Lebrun, A., Coubes, P., Picot, M.C., Baldy-Moulinier, M., Bockaert, J., Crespel, A., Lerner-Natoli, M. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain, 2007, 130(Pt 7), 1942-1956.
55. Chuang Y.C., Chen, S.D., Lin, T.K., Chang, W.N., Lu, C.H., Liou, C.W., Chan, S.H., Chang, A.Y. Transcriptional upregulation of nitric oxide synthase II by nuclear factor-kappaB promotes apoptotic neuronal cell death in the hippocampus following experimental status epilepticus. J. Neurosci. Res., 2010, 88(9), 1898-1907.
56. Lubin, F.D., Ren, Y., Xu, X., Anderson, A.E. Nuclear factor-kappa B regulates seizure threshold and gene transcription following convulsant stimulation. J. Neurochem., 2007, 103(4), 1381-1395.
57. Magni D.V., Souza, M.A., Oliveira, A.P., Furian, A.F., Oliveira, M.S., Ferreira, J., Santos, A.R., Mello, C.F., Royes, L.F., Fighera, M.R. Lipopolysaccharide enhances glutaric acid-induced seizure susceptibility in rat pups: behavioral and electroencephalographic approach. Epilepsy Res., 2011, 93(2-3), 138-148.
58. Rijkers, K., Majoie, H.J., Hoogland, G., Kenis, G., De Baets, M., Vles, J.S. The role of interleukin-1 in seizures and epilepsy: a critical review. Exp. Neurol., 2009, 216(2), 258-271.
59. van Vliet, E.A., da Costa Araújo, S., Redeker, S., van Schaik, R., Aronica, E., Gorter, J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain, 2007, 130(Pt 2), 521-534.
60. Irani S.R., Bien, C.G., Lang, B. Autoimmune epilepsies. Curr. Opin. Neurol., 2011, 24(2), 146-153.
61. Cojocaru, I.M., Cojocaru, M. Reactions of the immune system in epilepsy. Maedica (Buchar), 2010, 5(3), 201-206.
62. Illingworth M.A., Hanrahan, D., Anderson C.E., O'Kane, K., Anderson, J., Casey, M., de Sousa C., Cross, J.H., Wright S., Dale, R.C., Vincent, A., Kurian, M.A. Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Dev. Med. Child. Neurol., 2011, 53(11), 1053-1057.
63. Errichiello, L., Striano, S., Zara, F., Striano, P. Temporal lobe epilepsy and anti glutamic acid decarboxylase autoimmunity. Neurol. Sci., 2011, 32(4), 547-550.
64. Levite, M. Autoimmune epilepsy. Nat. Immunol., 2002, 3(6), 500.
65. Zuliani, L., Graus, F., Giometto, B., Bien, C., Vincent, A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J. Neurol. Neurosurg. Psychiatry, 2012, 83(6), 638-645.
66. Suleiman, J., Brenner, T., Gill, D., Troedson, C., Sinclair, A.J., Brilot, F., Vincent, A., Lang, B., Dale, R.C. Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies. Dev. Med. Child. Neurol., 2011, 53(11), 1058-1060.
67. Tsutsui, K., Kanbayashi, T., Tanaka, K., Boku, S., Ito, W., Tokunaga, J., Mori, A., Hishikawa, Y., Shimizu, T., Nishino, S. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry, 2012, 12(1), 37.
68. Mantegazza, R., Bernasconi, P., Baggi, F., Spreafico, R., Ragona, F., Antozzi, C., Bernardi, G., Granata, T. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J. Neuroimmunol., 2002, 131(1-2), 179-185.
69. Miesbach, W., Chapman, J., Scharrer, I. Focal seizures after treatment with fluvastatin in a patient with a history of catastrophic antiphospholipid syndrome. J. Neurol. Sci., 2005, 238(1-2), 93-95.
70. Wiendl, H., Bien, C.G., Bernasconi, P., Fleckenstein, B., Elger, C.E., Dichgans, J., Mantegazza, R., Melms, A. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology, 2001, 57(8), 1511-1514.
71. Irani, S.R., Vincent A. NMDA receptor antibody encephalitis. Curr. Neurol. Neurosci. Rep., 2011, 11(3), 298-304.
72. McKnight, K., Jiang, Y., Hart, Y., Cavey, A., Wroe, S., Blank, M., Shoenfeld Y., Vincent, A., Palace, J., Lang, B. Serum antibodies in epilepsy and seizure-associated disorders. Neurology, 2005, 65(11), 1730-1736.
73. Takahashi, Y., Mine, J., Kubota, Y., Yamazaki, E., Fujiwara, T. A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFalpha, and Granzyme B in CSF. Epilepsia, 2009, 50(6), 1419-1431.
74. Kirkpatrick, M.P., Clarke, C.D., Sonmezturk, H.H., Abou-Khalil, B. Rhythmic delta activity represents a form of nonconvulsive status epilepticus in anti-NMDA receptor antibody encephalitis. Epilepsy Behav., 2011, 20(2), 392-394.
75. Modoni, A., Masciullo, M., Spinelli, P., Marra, C., Tartaglione, T., Andreetta F., Tonali, P., Silvestri G. Successful treatment of acute autoimmune limbic encephalitis with negative VGKC and NMDAR antibodies. Cogn. Behav. Neurol., 2009, 22(1), 63-66.
76. Graeber, M.B., Li, W., Rodriguez, M.L. Role of microglia in CNS inflammation. FEBS Lett., 2011, 585(23), 3798-3805.
77. Polazzi, E, Monti, B. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog. Neurobiol., 2010, 92(3), 293-315.
78. Herrera-Peco, I., Sola, R.G., Osejo V., Wix-Ramos, R., Pastor, J. Role of astrocytes activated by albumin in epileptogenesis. Rev. Neurol., 2008, 47(11), 582-597.
79. Ravizza, T., Gagliardi, B., Noé, F., Boer, K., Aronica, E., Vezzani, A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures:evidence from experimental models and human temporal lobe epilepsy. Neurobiol. Dis., 2008, 29(1), 142-160.
80. Zattoni, M., Mura, M.L., Deprez, F., Schwendener, R.A., Engelhardt, B., Frei K., Fritschy, J.M. Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. J. Neurosci., 2011, 31(11), 4037-4050.
81. Marcon, J., Gagliardi, B., Balosso, S., Maroso, M., Noé, F., Morin, M., Lerner-Natoli, M., Vezzani, A., Ravizza, T. Age-dependent vascular changes induced by status epilepticus in rat forebrain: implications for epileptogenesis. Neurobiol. Dis., 2009, 34(1), 121-132.
82. Sloviter, R.S. The functional organization of the hippocampal dentate gyrus and its relevance to the pathogenesis of temporal lobe epilepsy. Ann. Neurol., 1994, 35(6), 640-654.
83. Coulter, D.A., Eid, T. Astrocytic regulation of glutamate homeostasis in epilepsy. Glia, 2012, 60(8), 1215-1226.
84. Domijan, A.M., Kovac, S., Abramov, A.Y. Impact of fumonisin B1 on glutamate toxicity and low magnesium-induced seizure activity in neuronal primary culture. Neuroscience, 2012, 202, 10-16.
85. Nemani, V.M., Binder, D.K. Emerging role of gap junctions in epilepsy. Histol. Histopathol. 2005, 20(1), 253-259.
86. Jin, M.M., Chen Z. Role of gap junctions in epilepsy. Neurosci. Bull., 2011, 27(6), 389-406.
87. Aronica, E., Gorter, J.A., Jansen, G.H., Leenstra, S., Yankaya, B., Troost, D. Expression of connexin 43 and connexin 32 gapjunction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol., 2001, 101(5), 449-459.
88. Fonseca, C.G., Green, C.R., Nicholson, L.F. Upregulation in astrocytic connexin 43 gap junction levels may exacerbate generalized seizures in mesial temporal lobe epilepsy. Brain Res., 2002, 929(1), 105-116.
89. Eid, T., Williamson, A., Lee, T.S., Petroff, O.A., de Lanerolle, N.C. Glutamate and astrocytes--key players in human mesial temporal lobe epilepsy? Epilepsia, 2008, 49(Suppl 2), 42-52.
90. Aronica, E., Gorter, J.A., Jansen, G.H., Leenstra, S., Yankaya, B., Troost, D. Expression of connexin 43 and connexin 32 gapjunction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol., 2001, 101(5), 449-459.
91. Morris, B.S., Nagar, A.M., Morani, A.C., Chaudhary, R.K., Garg, P.A., Chudgar, P.D., Raut A.A. Blood-fluid levels in the brain. Br. J. Radiol., 2007, 80(954), 488-498.
92. Spector, R. Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J. Neurochem., 2010, 112(1), 13-23.
93. Fabene, P.F., Navarro, M.G., Martinello, M., Rossi, B., Merigo, F., Ottoboni, L., Bach, S., Angiari, S., Benati, D., Chakir, A., Zanetti, L., Schio, F., Osculati A., Marzola, P., Nicolato, E., Homeister, J.W., Xia, L., Lowe, J.B., McEver R.P., Osculati, F., Sbarbati, A., Butcher, E.C., Constantin, G. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat. Med., 2008, 14(12), 1377-1383.
94. Katagiri F., Ishikawa M., Yamada Y., Hozumi K., Kikkawa Y., Nomizu M. Screening of integrin-binding peptides from the laminin α4 and α5 chain G domain peptide library. Arch. Biochem. Biophys., 2012, 521(1-2):32-42.
95. Grailer, J.J., Kodera, M., Steeber, D.A. L-selectin: role in regulating homeostasis and cutaneous inflammation. J. Dermatol. Sci., 2009, 56(3), 141-147.
96. Löscher, W., Potschka, H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci., 2005, 6(8), 591-602.
97. Chayasirisobhon, S. The mechanisms of medically refractory temporal lobe epilepsy. Acta, Neurol., Taiwan, 2009, 18(3):155-560.
98. Lazarowski, A., Czornyj, L., Lubienieki, F., Girardi, E., Vazquez, S., D'Giano, C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia, 2007, 48 (Suppl 5), 140-9.
99. van Vliet, E.A., van Schaik, R., Edelbroek, P.M., Redeker, S., Aronica, E., Wadman, W.J., Marchi, N., Vezzani, A., Gorter, J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia, 2006, 47(4), 672-680.
100. van Vliet, EA., Zibell, G., Pekcec, A., Schlichtiger, J., Edelbroek, PM., Holtman, L., Aronica, E., Gorter, J.A., Potschka, H. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology, 2010, 58(2), 404-412.
101. Holtman, L., van Vliet, E.A., Edelbroek, P.M., Aronica, E., Gorter, J.A. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. Epilepsy Res., 2010, 91(1), 49-56.
102. Matsuoka, Y., Kitamura, Y., Okazaki, M., Terai, K., Taniguchi, T. Kainic acid-induced activation of nuclear factor-kappa B in rat hippocampus. Exp. Brain Res., 1999, 124(2), 215-222.
103. Bauer, B., Hartz, A.M., Miller, D.S. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol. Pharmacol., 2007, 71(3), 667-675.
104. Lee, J.S., Jung, I.D., Lee, C.M., Noh K.T., Park, J.W., Son, K.H., Heo, D.R., Shin, Y.K., Kim, D., Park, Y.M. Venlafaxine inhibits the development and differentiation of dendritic cells through the regulation of P-glycoprotein. Int. Immunopharmacol., 2011, 11(9), 1348-1357.
105. Kooij, G., Backer, R., Koning, J.J., Reijerkerk, A., van Horssen, J., van der Pol, S.M., Drexhage, J., Schinkel, A., Dijkstra, C.D., den Haan, J.M., Geijtenbeek, T.B., de Vries, H.E. P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One, 2009, 4(12), e8212.
106. Vincent, A., Crino, P.B. Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia, 2011, 52(Suppl 3), 12-17.
107. Al-Araji, A., Kidd, D.P. Neuro-Behçet's disease: epidemiology., clinical characteristics, and management. Lancet Neurol., 2009, 8(2), 192-204.
108. Aktekin, B., Doǧan, E.A., Oǧuz, Y., Karaali, K. Epilepsia partialis continua in a patient with Behçet's disease. Clin. Neurol. Neurosurg., 2006, 108(4), 392-395.
109. de Holanda, N.C., de Lima, D.D., Cavalcanti, T. B., Lucena, C.S., Bandeira, F. Hashimoto's encephalopathy: systematic review of the literature and an additional case. J. Neuropsychiatry Clin. Neurosci., 2011, 23(4), 384-390.
110. Popescu, A., Kao, A.H. Neuropsychiatric systemic lupus erythematosus. Curr. Neuropharmacol., 2011, 9(3), 449-457.
111. Sanna, G., Bertolaccini, M.L., Khamashta, M.A. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr. Pharm. Des., 2008, 14(13), 1261-1269.
112. Appenzeller, S., Cendes, F., Costallat, L.T. Epileptic seizures in systemic lupus erythematosus. Neurology, 2004, 63(10), 1808-1812.
113. Lim, K.S., Cheong, K.L., Tan, C.T. Periodic lateralized epileptiform discharges in neuropsychiatric lupus: association with cerebritis in magnetic resonance imaging and resolution after intravenous immunoglobulin. Lupus, 2010, 19(6), 748-752.
114. Butler, S., Malone, R.J. Seizure as a presenting symptom in neuropsychiatric systemic lupus erythematosus. Am. J. Phys. Med. Rehabil., 2010, 89(4), 349.
115. Compston, A., Coles, A. Multiple sclerosis. Lancet, 2002, 359(9313), 1221-1231.
116. Haensch, C.A., Jörg, J. Autonomic dysfunction in multiple sclerosis. J. Neurol., 2006, 253(Suppl 1), I3-9.
117. Poser, C.M., Brinar, V.V. Epilepsy and multiple sclerosis. Epilepsy Behav., 2003, 4(1), 6-12.
118. Koch, M., Uyttenboogaart, M., Polman, S., De Keyser, J. Seizures in multiple sclerosis. Epilepsia, 2008, 49(6), 948-953.
119. Roberts, D.J., Goralski., K.B. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert. Opin. Drug Metab. Toxicol., 2008, 4(10), 1-20.
120. Specchio, N., Fusco, L., Claps, D., Trivisano, M., Longo, D., Cilio, M.R., Valeriani, M., Cusmai, R., Cappelletti, S., Gentile, S., Fariello, G., Specchio, L.M., Vigevano, F. Childhood refractory focal epilepsy following acute febrile encephalopathy. Eur. J. Neurol., 2011, 18(7), 952-961.
121. Snead, O.C., Benton, J.W., Myers, G.J. ACTH and prednisone in childhood seizure disorders. Neurology, 1983, 33(8), 966-970.
122. Tolmacheva, E.A., Oitzl, M.S., van Luijtelaar, G. Stress glucocorticoids and absences in a genetic epilepsy model. Horm. Behav., 2012, 61(5), 706-710.
123. Haberlandt, E., Weger, C., Sigl, S.B., Rauchenzauner, M., Scholl-Bürgi, S., Rostásy, K., Karall, D. Adrenocorticotropic hormone versus pulsatile dexamethasone in the treatment of infantile epilepsy syndromes. Pediatr. Neurol., 2010, 42(1), 21-27.
124. Gayatri, N.A., Ferrie, C.D., Cross, H. Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms. Cochrane Database Syst. Rev., 2007, (1), CD005222.
125. Haberlandt, E., Weger, C., Sigl, S.B., Rauchenzauner, M., Scholl-Bürgi, S., Rostásy, K., Karall, D. Adrenocorticotropic hormone versus pulsatile dexamethasone in the treatment of infantile epilepsy syndromes. Pediatr. Neurol., 2010, 42(1):21-27.
126. Marchi, N., Granata, T., Freri, E., Ciusani, E., Ragona, F., Puvenna, V., Teng, Q., Alexopolous, A., Janigro, D. Efficacy of anti inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One, 2011, 6(3), e18200.
127. Kang, S.H., Lee, J.Y., Park, H.S., Sun, I.O., Choi, S.R., Chung, B.H., Choi, B.S., Yang, C.W., Kim, Y.S., Park, C.W. Hyperglycemic hyperosmolar syndrome caused by steroid therapy in a patient with lupus nephritis. J. Korean Med. Sci., 2011, 26(3), 447-449.
128. Grosso, S., Farnetani, M., Mostardini, R., Cordelli, D., Berardi, R., Balestri, P. A comparative study of hydrocortisone versus deflazacort in drug-resistant epilepsy of childhood. Epilepsy Res., 2008, 81(1), 80-85.
129. Nohria, V., Giller, E. Ganaxolone. Neurotherapeutics, 2007, 4(1), 102-105.
130. Pieribone, V.A., Tsai, J., Soufflet, C., Rey, E., Shaw, K., Giller, E., Dulac, O. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia, 2007, 48(10), 1870-1874.
131. Reddy, D.S., Mohan, A. Development and persistence of limbic epileptogenesis are impaired in mice lacking progesterone receptors. J. Neurosci., 2011, 31(2), 650-658.
132. Reddy, D.S., Gangisetty, O., Briyal, S. Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Neuropharmacology, 2010, 59(7-8), 573-581.
133. van Rijckevorsel-Harmant, K., Delire, M., Rucquoy-Ponsar, M. Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins. Eur. Arch. Psychiatry Neurol. Sci., 1986, 236(2), 119-22.
134. Plebani, A., Duse, M., Tiberti, S., Avanzini, M.A., Monafo, V., Menegati, E., Ugazio, A.G., Burgio, G.R. Intravenous gammaglobulin therapy and serum IgG subclass levels in intractable childhood epilepsy. Monogr. Allergy, 1988, 23, 204-215.
135. Arts, W.F., Aarsen, F.K., Scheltens-de Boer, M., Catsman-Berrevoets, C.E. Landau-Kleffner syndrome and CSWS syndrome: treatment with intravenous immunoglobulins. Epilepsia, 2009, 50(Suppl 7), 55-58.
136. Fois, A., Vascotto, M. Use of intravenous immunoglobulins in drug-resistant epilepsy. Childs Nerv. Syst., 1990, 6(7), 400-405.
137. Van Rijckevorsel, K., Delire, M. Immunoglobulin treatment in human and experimental epilepsy. J. Neurol. Neurosurg. Psychiatry., 1995, 59(1):105.
138. Mikati, M.A., Kurdi, R., El-Khoury, Z., Rahi, A., Raad, W. Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature. Epilepsy Behav., 2010, 17(1), 90-94.
139. van Engelen, B.G., Renier, W.O., Weemaes, C.M., Gabreels, F.J., Meinardi, H. Immunoglobulin treatment in epilepsy., a review of the literature. Epilepsy Res., 1994, 19(3), 181-190.
140. Billiau, A.D., Witters, P., Ceulemans, B., Kasran, A., Wouters, C., Lagae, L. Intravenous immunoglobulins in refractory childhoodonset epilepsy: effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile. Epilepsia, 2007, 48(9), 1739-1749.
141. Arts, W.F., Aarsen, F.K., Scheltens-de Boer, M., Catsman-Berrevoets, C.E. Landau-Kleffner syndrome and CSWS syndrome: treatment with intravenous immunoglobulins. Epilepsia, 2009, 50(Suppl 7), 55-58.
142. Marchi, N., Fan, Q., Ghosh, C., Fazio, V., Bertolini, F., Betto, G., Batra, A., Carlton, E., Najm, I., Granata, T., Janigro D. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol. Dis., 2009, 33(2), 171-181.
143. Vezzani, A., Balosso, S., Maroso, M., Zardoni, D., Noé, F., Ravizza, T. ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr. Opin. Investig. Drugs, 2010, 11(1), 43-50.
144. Godukhin, O.V., Levin, S.G., Parnyshkova, E.Y. The effects of interleukin-10 on the development of epileptiform activity in the hippocampus induced by transient hypoxia., bicuculline., and electrical kindling. Neurosci. Behav. Physiol., 2009, 39(7), 625-631.
145. Matsuo, M., Sasaki, K., Ichimaru, T., Nakazato, S., Hamasaki, Y. Increased IL-1beta production from dsRNA-stimulated leukocytes in febrile seizures. Pediatr. Neurol., 2006, 35(2), 102-106.
146. Jiang, J., Ganesh, T., Du, Y., Quan, Y., Serrano, G., Qui, M., Speigel, I., Rojas, A., Lelutiu, N., Dingledine, R. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc. Natl. Acad. Sci. U. S. A., 2012, 109(8), 3149-3154.
147. Bergey, G.K. Autoantibodies in the Patient With Drug-Resistant Epilepsy: Are We Missing a Treatable Etiology? Arch Neurol., 2012, 69(5), 565-566.
148. Reichert, J.M. Marketed therapeutic antibodies compendium. MAbs., 2012, 4(3), 413-415.
149. Joshi, A., Bauer, R., Kuebler, P., White, M., Leddy, C., Compton, P., Garovoy, M., Kwon, P., Walicke, P., Dedrick, R. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J. Clin. Pharmacol., 2006, 46(1), 10-20.
150. Gaber, A.O., Mulgaonkar, S., Kahan, B.D., Woodle, E.S., Alloway, R., Bajjoka, I., Jensik, S., Klintmalm, G.B., Patton, P.R., Wiseman, A., Lipshutz, G., Kupiec-Weglinski, J., Gaber, L.W., Katz, E., Irish, W., Squiers, E.C., Hemmerich S. YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study. Clin. Transplant., 2011, 25(4), 523-533.
151. Kino, T., Hatanaka, H., Hashimoto, M., Nishiyama, M., Goto, T., Okuhara, M., Kohsaka, M., Aoki, H., Imanaka, H. FK-506., a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot (Tokyo)., 1987, 40(9), 1249-1255.
152. Chwiej, J., Janeczko, K., Marciszko, M., Czyzycki, M., Rickers, K., Setkowicz, Z. Neuroprotective action of FK-506 (tacrolimus) after seizures induced with pilocarpine: quantitative and topographic elemental analysis of brain tissue. J. Biol. Inorg. Chem., 2010, 15(2), 283-289.
153. Setkowicz, Z., Ciarach, M. Neuroprotectants FK-506 and cyclosporin A ameliorate the course of pilocarpine-induced seizures. Epilepsy Res., 2007, 73(2), 151-155.
154. Suzuki, K., Omura, S., Ohashi, Y., Kawai, M., Iwata, Y., Tani, K., Sekine, Y., Takei, N., Mori, N. FK506 facilitates chemical kindling induced by pentylenetetrazole in rats. Epilepsy Res., 2001, 46(3), 279-282.
155. Chrzaszcz, M., Venkatesan, C., Dragisic, T., Watterson, D.M., Wainwright, M.S. Minozac treatment prevents increased seizure susceptibility in a mouse "two-hit" model of closed skull traumatic brain injury and electroconvulsive shock-induced seizures. J. Neurotrauma, 2010, 27(7), 1283-1295.
156. Lloyd, E., Somera-Molina, K., Van Eldik, L.J., Watterson, D.M., Wainwright, M.S. Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J. Neuroinflammation, 2008, 5, 28.
157. Antozzi, C., Granata, T., Aurisano, N., Zardini, G., Confalonieri, P., Airaghi, G., Mantegazza, R., Spreafico, R. Long-term selective IgG immuno-adsorption improves Rasmussen's encephalitis. Neurology, 1998, 51(1), 302-305.
158. Beghi, E., Shorvon, S. Antiepileptic drugs and the immune system. Epilepsia, 2011, 52(Suppl 3), 40-44.
159. Engel, J. Jr., Wiebe, S., French, J., Sperling, M., Williamson, P., Spencer, D., Gumnit, R., Zahn, C., Westbrook, E., Enos, B. Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society; American Association of Neurological Surgeons. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology, 2003, 25, 60(4), 538-547.
160. Meregnani, J., Clarençon, D., Vivier, M., Peinnequin, A., Mouret, C., Sinniger, V., Picq, C., Job, A., Canini, F., Jacquier-Sarlin, M., Bonaz, B. Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease. Auton. Neurosci., 2011, 160(1-2), 82-89.
161. Lambrechts, D.A., Wielders L.H., Aldenkamp, A.P., Kessels, F.G., de Kinderen, R.J., Majoie, M.J. The ketogenic diet as a treatment option in adults with chronic refractory epilepsy: efficacy and tolerability in clinical practice. Epilepsy Behav., 2012, 23(3), 310-314.
162. Jeon, B.T., Lee, D.H., Kim, K.H., Kim, H.J., Kang, S.S., Cho, G.J., Choi, W.S., Roh, G.S. Ketogenic diet attenuates kainic acidinduced hippocampal cell death by decreasing AMPK/ACC pathway activity and HSP70. Neurosci. Lett., 2009, 453(1), 49-53.
163. Reti, I.M., Walker, M., Pulia, K., Gallegos, J., Jayaram, G., Vaidya, P. Safety considerations for outpatient electroconvulsive therapy. J. Psychiatr. Pract., 2012, 18(2), 130-136.
164. Oshima, H., Katayama, Y., Morishita, T., Sumi, K., Otaka, T., Kobayashi, K., Suzuki, Y., Fukaya, C., Yamamoto, T. Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease. J. Neurosurg., 2012, 116(1), 99-106.
165. Shetty, A.K., Hattiangady, B. Concise review: prospects of stem cell therapy for temporal lobe epilepsy. Stem Cells, 2007, 25(10), 2396-2407.